TG Therapeutics
Adam Waldman joined TG Therapeutics in June of 2018 as the Chief Commercialization Officer. Most recently, Mr. Waldman served as the Head of Hematology-Oncology Marketing at Celgene Corporation where he spent the past thirteen years in various roles of increasing responsibility in sales, marketing, and new product strategy. Adam brings extensive experience and a proven track record of success building high-performing teams and launching transformational products in both hematology and oncology. Prior to Celgene, Mr. Waldman was at Schering Plough where he was responsible for coordinating the global marketing strategy for multiple oncology products. Mr. Waldman holds an MBA in Finance from the University of Rochester, Simon Business School, as well as a B.S. in Biological Science from Rutgers College.
This person is not in any offices
TG Therapeutics
2 followers
TG Therapeutics is a fully-integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.